Strategic Partnerships Potential collaboration opportunities with behavioral health providers and psychiatry networks given Genesight’s pharmacogenomics testing focus and recent partnerships with Catalyst Psychiatry and mental health care providers.

Clinical Expansion Target growth through regional hospital systems and specialty clinics expanding pharmacogenomic testing for psychotropic and oncology meds, leveraging Genesight’s history as a pioneer in PGx testing.

Pharmacogenomics Adoption Capitalize on demand for personalized medicine by offering scalable PGx solutions to clinics and telehealth platforms serving behavioral health, leveraging the company’s long-standing PGx test lab capabilities.

Enterprise Growth Engage mid-market and large practice groups similar to Brookfield Asset Management–affiliated networks to onboard broader provider organizations, expanding the Genesight test footprint.

Clinical & Data Opportunities Leverage data from the GeneSight Mental Health Monitor and other studies to develop value propositions around safer prescribing, patient outcomes analytics, and payer-facing cost-savings narratives for mental health treatment.